Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

146.88
+0.27000.18%
Post-market: 146.880.00000.00%16:10 EDT
Volume:260.35K
Turnover:38.39M
Market Cap:5.19B
PE:-8.19
High:149.85
Open:146.39
Low:146.39
Close:146.61
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:1.03
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.53
PE(LYR):-5.82

Loading ...

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

GlobeNewswire
·
Yesterday

Xero Stock And 2 AI Software Picks Retail Investors Should Watch

Simply Wall St.
·
Aug 23

PELL Bio-Med's Multi-chain CAR-T Technology Gets Patent in Japan

MT Newswires Live
·
Aug 21

AI Stocks To Watch As Demand Lifts SEEK Xero And CAR Group

Simply Wall St.
·
Aug 21

Is Avis Budget Group (CAR) Fairly Valued On Class Action Lawsuit News?

Simply Wall St.
·
Aug 20

Press Release: CARsgen Therapeutics Announces 2026 Interim Results

Dow Jones
·
Aug 19

Xero Stock And 2 Australian AI Shares Backed By Real World Software Use

Simply Wall St.
·
Aug 18

CARsgen narrows loss and boosts cash on CAR T sales and top-up placing

TIPRANKS
·
Aug 18

3 AI Stocks Riding Real Demand For Cloud And Chip Infrastructure

Simply Wall St.
·
Aug 17

How Investors May Respond To CAR Group (ASX:CAR) FY26 Results And FY27 Growth Guidance

Simply Wall St.
·
Aug 17

AI Stocks To Watch Now As Higher Bond Yields Test Software Leaders

Simply Wall St.
·
Aug 16

AI Stocks To Watch As Chip Demand Lifts Software Growth

Simply Wall St.
·
Aug 15

Avis Budget Group Balances Earnings Strength With Risks

TIPRANKS
·
Aug 15

Beijing's New Policies Drive Cell Therapy Sector with Payment and Approval Reforms, Sparking Industry-wide Value Reassessment

Deep News
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewswire
·
Aug 14

Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Tyler Van Buren Reiterates Buy on Allogene, Citing Strong ALPHA3 Trial Momentum and De-Risking Efficacy/Safety Data for Off-the-Shelf CAR-T Cema-cel

TIPRANKS
·
Aug 13

Xero Stock And 2 Australian AI Shares With Real Business Use

Simply Wall St.
·
Aug 13

CAR Group Bulls See EV Adoption as a Tailwind

Dow Jones
·
Aug 13